Citigroup Inc Ascendis Pharma A/S Put Options Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 12, 2024	SELL	$113.0 - $153.43 $1.13 Million - $1.53 Million	-10,000 Reduced 80.0%	2,500 $373,000
Q2 2024 Aug 12, 2024	SELL	$121.07 - $153.67 $1.49 Million - $1.89 Million	-12,300 Reduced 49.6%	12,500 $1.7 Million
Q4 2023 Feb 09, 2024	SELL	$86.1 - $127.36 $2.31 Million - $3.41 Million	-26,800 Reduced 51.94%	24,800 $3.12 Million
Q3 2023 Nov 09, 2023	BUY	$86.5 - $103.97 $2.3 Million - $2.77 Million	26,600 Added 106.4%	51,600 $4.83 Million
Q1 2023 May 11, 2023	BUY	$104.9 - $126.78 $83,920 - $101,424	800 Added 3.31%	25,000 $2.68 Million
Q4 2022 Feb 09, 2023	BUY	$99.42 - $131.97 $2.41 Million - $3.19 Million	24,200 New	24,200 $2.96 Million

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.